{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-26-000017","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.806335+00:00","generated_at":"2026-05-15T21:42:29.975957+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Keros Therapeutics reports Q4 net loss $23.5M, full-year net income $87.0M","bullets":["Q4 2025 net loss $23.5M vs. $46.0M loss in Q4 2024; FY 2025 net income $87.0M vs. $187.4M loss in FY 2024.","Cash and equivalents $287.4M as of Dec 31, 2025, expected to fund operations into first half of 2028.","R&D expenses fell to $17.9M (Q4) and $129.6M (FY) due to transition of elritercept costs to Takeda.","Charles Newton appointed to board effective March 9, 2026; Carl Gordon steps down. Esther Cho promoted to Chief Legal Officer.","Phase 2 trial of rinvatercept for DMD expected to start in Q2 2026; ALS regulator engagement planned for H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-26-000017","json":"https://secwatch.observer/filing/0001664710-26-000017.json","markdown":"https://secwatch.observer/filing/0001664710-26-000017.md","text":"https://secwatch.observer/filing/0001664710-26-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000017/0001664710-26-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000017/kros-20260304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:42:29.975957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}